MedTrace Logo

Insulin Therapy in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations

NCT00467636 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2009-10-02

No results posted yet for this study

Summary

The purpose of this study is to determine the effect of preventing hyperglycaemia in patients admitted to hospital with acute exacerbations of chronic pulmonary disease.

Conditions

Interventions

PROCEDURE

Blood glucose monitoring

Regular pre and post meal blood glucose monitoring.

DRUG

Insulin Glulisine

Sub cutaneous injection given twice daily for 3 days. Dosage titrated to body mass index and body weight (BMI \< 30 = 0.1 unit/kg. BMI \> 30 = 0.2 unit/kg)

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • The Royal Bournemouth Hospital

    lead OTHER

Principal Investigators

  • David Kerr, MD · Royal Bournemouth Hospital NHS Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00467636 on ClinicalTrials.gov